DexCom (DXCM) Revenue — Quarter Ended Sep 30, 2024
Revenue for the quarter declined compared with the immediately preceding period but rose relative to the same period a year earlier. The filing contained standard forward-looking cautionary language and no specific commentary on the revenue movement.
Key takeaway
Quarter ended Sep 30, 2024 · FY2024 Q3
Revenue for the quarter declined compared with the immediately preceding period but rose relative to the same period a year earlier. The filing contained standard forward-looking cautionary language and no specific commentary on the revenue movement.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$994.2M
Revenue reported for this quarter.
Quarter-over-quarter
-1.0%
Change from the immediately preceding quarter.
Year-over-year
+2.0%
Change from the comparable year-ago quarter.
Trailing four quarters
$4B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2023 | $1B | +26.9% |
| Mar 31, 2024 | $921M | +24.2% |
| Jun 30, 2024 | $1B | +15.3% |
| Sep 30, 2024 | $994.2M | +2.0% |
Revenue performance
The reported revenue decreased from the prior quarter, but increased from the same quarter one year ago. This marks a shift from the sequential growth seen in earlier quarters of the trailing twelve months.
Quarterly comparison
Compared to the immediately preceding quarter, revenue was lower. Versus the same quarter a year earlier, revenue was higher — a moderation in the year-over-year growth rate compared to recent trends.
What to watch
The filing provided no specific explanation for the quarterly revenue decline; investors may look for operational updates in future filings.